Tim Adams
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- COVID-19 Clinical Research Studies 6
-
- Infant Development and Preterm Care 1
- Co-authors
- Steve Cunningham (1 shared paper)Steve Turner (1 shared paper)Aryelly Rodríguez (1 shared paper)Kathleen Boyd (1 shared paper)Beth Enderby (1 shared paper)Emma McIntosh (1 shared paper)Isabella Butcher (1 shared paper)James Y. Paton (1 shared paper)
- Partner nations
- United KingdomVietnamNepal
In The Last Decade
Tim Adams
9 papers receiving 1.7k citations
Tim Adams's Hit Papers
Peers
Comparison fields: 5 of 82
- Infectious Diseases 1.3k
- Applied Microbiology and Biotechnology 36
- Internal Medicine 27
- Epidemiology 141
- Statistics and Probability 48
Countries citing papers authored by Tim Adams
This map shows the geographic impact of Tim Adams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Adams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Adams more than expected).
Fields of papers citing papers by Tim Adams
This network shows the impact of papers produced by Tim Adams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Adams. The network helps show where Tim Adams may publish in the future.
Co-authors
The 12 scholars most cited alongside Tim Adams, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 5 | 2021 | 213 | |
| 6 | 2015 | 122 | |
| 7 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 8 | 2010 | 19 | |
| 9 | 2025 | 2 |
About Tim Adams
Tim Adams is a scholar working on Infectious Diseases, Pediatrics, Perinatology and Child Health, Physiology, Epidemiology and Nuclear Energy and Engineering, having authored 9 papers that have together received 1.8k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (6 papers), Asthma and respiratory diseases (1 paper), Infant Development and Preterm Care (1 paper) and Respiratory viral infections research (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Applied Microbiology and Biotechnology (36 citations), Internal Medicine (27 citations), Epidemiology (141 citations) and Statistics and Probability (48 citations). Tim Adams has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Frequent co-authors include Steve Cunningham, Steve Turner, Aryelly Rodríguez, Kathleen Boyd, Beth Enderby, Emma McIntosh, Isabella Butcher, James Y. Paton, Jonathan McCormick and Fiona Wee. Their work appears in journals such as The Lancet, BMC Medical Research Methodology and JAMA Network Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.